The Medicines Company clinical trials

Acquired by Novartis, Jan 6, 2020 · source ↗

The registry lists 50 studies whose lead sponsor is The Medicines Company. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 1, 2024.

Studies

Recruiting first, then most recently updated. Showing 50 of 50. All Novartis studies →

• Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure InfectionCompletedNCT02925416Phase 4

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)CompletedNCT02452918Phase 4

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy VolunteersCompletedNCT02471690Phase 1

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT03397121Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHFWithdrawnNCT04592380Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted after The Medicines Company became part of Novartis

• Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) PatientsWithdrawnNCT00759083Phase 4

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein CholesterolCompletedNCT03399370Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein CholesterolCompletedNCT03400800Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT02963311Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Cangrelor to Clopidogrel or Prasugrel Transition StudyCompletedNCT01979445Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)CompletedNCT02597127Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)CompletedNCT00073580Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)CompletedNCT03159416Phase 1

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Bivalirudin Infusion for Ventricular Infarction LimitationTerminatedNCT02565147Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Association Between Patients' Perceptions of Success in Post-op Pain Management and Overall Experience With CareWithdrawnNCT02389907

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an EvaluationCompletedNCT01860105Phase 1

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing ColonoscopyCompletedNCT02800590Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric ParticipantsCompletedNCT02395653Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers TrialCompletedNCT02678923Phase 1/2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• ENDOvascular Interventions With AngioMAX: The ENDOMAX TrialTerminatedNCT01913483Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFHCompletedNCT01651780Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• European Ambulance Acute Coronary Syndrome (ACS) Angiography TrialCompletedNCT01087723Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac SurgeryTerminatedNCT01530399Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Cangrelor Prasugrel Transition StudyCompletedNCT01852019Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)CompletedNCT00799604Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)CompletedNCT00803634Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)CompletedNCT00666328Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)CompletedNCT00093249Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)CompletedNCT00369837Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Cangrelor Ticagrelor Transition StudyCompletedNCT01766466Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)CompletedNCT00093262Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• A Clinical Trial to Demonstrate the Efficacy of CangrelorTerminatedNCT00305162Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)CompletedNCT00093925Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)CompletedNCT00093886Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)CompletedNCT00093912Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.TerminatedNCT00385138Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Maintenance of Platelet Inhibition With CangrelorCompletedNCT00767507Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)CompletedNCT01156571Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft SurgeryCompletedNCT01535222Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Utilisation of Angiox® in European PracticeCompletedNCT01011504

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy VolunteersCompletedNCT00699504Phase 1

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)CompletedNCT00079586Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Bivalirudin as a Procedural Anticoagulant in PediatricsCompletedNCT00503126Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Angiomax in Patients With HIT/HITTS Type II Undergoing CPBCompletedNCT00079508Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCABCompletedNCT00073593Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)CompletedNCT00043940Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Pharmacokinetics/Pharmacodynamics (PK/PD) of CangrelorCompletedNCT00102674Phase 1

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)CompletedNCT00093158Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCICompletedNCT00093184Phase 3

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis

• Study Of Angiomax In Infants Under Six Months With ThrombosisCompletedNCT00043277Phase 2

  Sponsor listed in the registry: The Medicines Company · First submitted before The Medicines Company became part of Novartis